Clinical trials: Liver Inflammation
Hepatitis C, Alcohol Use Disorder
HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
The primary objective of this research project is to compare neuropsychiatric functioning, cortical activity, white matter integrity, and immune response among Veterans with and without alcohol use disorder (AUD), before and…
- Trial name
- NCT03902366
- Testing
- Neuropsychological assessment, Neuroimaging
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
This was a multicenter study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with ribavirin (RBV) for 12 weeks in treatment naïve and pegylated-interferon alfa-2a or alfa-2b…
- Trial name
- Turquoise-IV (NCT02216422)
- Testing
- Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Ribavirin (RBV)
- Volunteers
- 36 people
- Sponsor
- AbbVie
Chronic Hepatitis B
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
The primary objectives of this study are to evaluate the safety and tolerability of the 12 week treatment regimens of inarigivir soproxil plus tenofovir alafenamide (TAF) or commercially available nucleoside/nucleotide (NUC) in…
- Trial name
- NCT03434353
- Testing
- Inarigivir Soproxil, TAF
- Where
- 13 sites in Hong Kong, South Korea
- Volunteers
- 123 people
- Sponsor
- Gilead Sciences
Tetanus, Hepatitis B
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.
- Conditions
- Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Poliomyelitis
- Trial name
- NCT01090453
- Testing
- GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™
- Where
- 34 sites in Canada, France and 1 more
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
This study will determine whether participants who receive the vaccine V419 at 2, 3, 4, and 12 months of age have an acceptable immune response to the vaccine.
- Trial name
- NCT01341639
- Testing
- V419, INFANRIX™ hexa, RotaTeq
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Autoimmune Hepatitis
Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial
The gold-standard treatment of Autoimmune hepatitis (AIH), with prednisone alone or in conjunction with azathioprine can reach resolution of the disease in 70-80% of the cases in US.
- Trial name
- NCT02463331
- Testing
- Chloroquine diphosphate, prednisone, azathioprine
- Volunteers
- 57 people
- Sponsor
- University of Sao Paulo General Hospital
Opioid Dependence, Addiction
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
The purpose of this study is to conduct empiric studies of tuberculosis (TB) among people in prison with and without a history of opioid dependence.
- Conditions
- Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis
- Trial name
- HARAPAN II (NCT03089983)
- Testing
- Isoniazid, Rifapentine
- Where
- Malaysia
- Volunteers
- 316 people
- Sponsor
- Yale University
Hepatitis C
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in treatment-naive and treatment-experienced…
- Trial name
- NCT01962441
- Testing
- SOF, RBV, Peg-IFN
- Where
- 78 sites in United States, Australia and 3 more
- Volunteers
- 601 people
- Sponsor
- Gilead Sciences
Intravenous Drug Usage, HIV/AIDS
Building on Needle Exchange to Optimize Prevention & Treatment
There are several biomedical interventions that can help people who inject drugs (particularly those with or at risk for HIV), but these services often do not get to the people most in need.
- Trial name
- NCT03567174
- Testing
- Integrated care van (ICV)
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- Johns Hopkins University
Hepatitis B, Chronic
Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study
This is a phase IV, single-arm, open-label, multi-centre study to assess the efficacy of TDF in Chronic hepatitis B (CHB) subjects following failure of multiple Nucleos(t)ide analogues (NAs).
- Trial name
- NCT02195518
- Testing
- Tenofovir disoproxil fumarate
- Where
- 12 sites in China
- Volunteers
- 213 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic, Chronic Hepatitis B
Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814
This is an open label, single-arm, multi-centre extension study for Korean patients with chronic hepatitis B and compensated liver disease who have completed one-year adefovir dipivoxil treatment in ADF103814.
- Trial name
- NCT00403585
- Testing
- adefovir dipivoxil 10mg
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection
The primary objectives of this study are to evaluate the effect of sustained virologic response (SVR) on cerebral metabolism as determined by magnetic resonance spectroscopy (MRS) and on neurocognition as measured by…
- Trial name
- NCT02219685
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus (HCV) Infection
Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)
The purpose of this study was to evaluate the efficacy of 8 and 12 weeks of treatment with a fixed dose combination (FDC) of elbasvir (EBR) 50 mg + grazoprevir (GZR) 100 mg (i.e., MK-5172A) as assessed by the percentage of…
- Trial name
- NCT03111108
- Testing
- EBR/GZR (50 mg/100 mg) FDC
- Where
- 13 sites in France
- Volunteers
- 117 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine
The aim of this Observer-blind study is to compare different Adjuvant Systems with the same, well-known antigen (HBsAg) already used in the GSK marketed vaccines against Hepatitis B (Engerix-BTM and FendrixTM), in order to better…
- Trial name
- NCT00805389
- Testing
- Engerix-B™, Fendrix™, GSK Biologicals' Hepatitis B vaccines (GSK223192A)
- Where
- 14 sites in Belgium, Germany
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B
This randomized study will be conducted in two parts to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931.
- Trial name
- NCT03038113
- Testing
- RO7062931, Immune Modulator
- Where
- 19 sites in Australia, Hong Kong and 5 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)
This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC.
- Trial name
- NCT02641379
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 21 sites in Austria
- Volunteers
- 737 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
The objective of this trial is to investigate tolerability, safety, pharmacokinetics and antiviral activity of BI 207127 NA in combination with BI 201335 NA and ribavirin for 8 weeks in Japanese treatment-naive patients with…
- Trial name
- NCT01528735
- Testing
- BI 207127 NA, peginterferon, Ribavirin
- Where
- 5 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Liver Fibrosis
Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to respond to anti-viral treatment are often concerned about their ongoing liver disease and are therefore looking for alternative treatments…
- Trial name
- NCT00180674
- Testing
- Warfarin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Imperial College London
Hepatitis B, Hepatitis A
Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™
This study will evaluate the immune response against Hepatitis-A (HAV) and Hepatitis B surface (HBs) antigen in healthy subjects aged 12 to 15 years (at the time of primary vaccination), who received vaccination course with GSK…
- Trial name
- NCT00875485
- Testing
- Blood sampling, Additional challenge dose
- Where
- 2 sites in Belgium, Czechia
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche…
- Trial name
- NCT00800735
- Testing
- Pegylated-interferon alfa-2a, Ribavirin
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.